2Badesch DB, Abman SH, Simolmeau G, et al. Medical therapy for pulmonary arterial hypertension. Chest, 2007,131:1917 - 1928.
3Cassandro R, Harari S. Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 2006,23(3) :165 -179.
4Morgan JE, Griffiths M, du Bois RM, et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and pulmonary hypertension. Chest, 1991,99:551 - 556.
5Frubwald FM, Kjellstrom B, Perthold W, et al. Continuous hemodynamic monitoring in pulmonary hypertension patients treated with inhaled iloprost. Chest, 2003,124:351 - 359.
6Ghofrani HA, Rose F, Schermuly R, et al. Oral sildenafil as longterm adjunt therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol, 2003,42:158 -164.
1Takaoka S, Faul JL, Doyle R. Current therapies for pulmonary arterial hypertension. Semin Cardiothorac Vasc Anesth, 2007, 11:137-148.
2Barst R J, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 1996, 334:296-302.
3Mclaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482.
4Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007, 93: 739-743.
5Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest, In press 2007.
6Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med, 2005,172 : 1586-1589.
7Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long- term epoprostenol ( prostacyclin ) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J, 1999,13:1351-1356.
8Barst R J, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2003, 41: 2119-2125.
9Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J, 2001, 17: 14-19.
10Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002, 346: 896- 903.
3Lilienfeld D E,Rubin L J. Mortality from primary pulmonary hypertension in the United States,1979-1996[J].Chest,2000,(03):796-800.
4Grifoni S,Vanni S,Magazzini S. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events[J].Archives of Internal Medicine,2006,(19):2151-2156.
5Dandel M,Lehmkuhl H B,Mulahasanovic S. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation:impact of iloprost and bosentan treatment[J].Journal of Heart and Lung Transplantation,2007,(09):898-906.
6Fernandez A,Guerra M F,Camino E. New etiopathogenic,diagnostic and therapeutic aspects in primary pulmonary hypertension[J].Annales de Medecine Interne,1995,(06):294-298.
